Neuromodulation Companies Market Position Advancements

Who are the Neuromodulation Market Top Companies and What are Their Offerings?

Recent Developments in the Neuromodulation Market

• In May 2026, a new TMS device costing $3,000 per month and easy to operate after a few hours of training was launched by Ampa. The Ampa One TMS system was approved in Israel, creating opportunities for its commercial launch overseas.
• In May 2026, a real-time, sensor-based Adaptive Deep Brain Stimulation (aDBS) system was launched by Medtronic for Parkinson's disease in India. This launch will expand its neuromodulation portfolio by adding aDBS as an advanced therapy to its neurological care.

Neuromodulation Market Value Chain Analysis

R&D

• The R&D of the neuromodulation focuses on the development of miniaturised wearable, AI-driven, and closed-loop systems.
• Key players: Medtronic plc, Boston Scientific Corporation, Abbott Laboratories.

Clinical Trials and Regulatory Approvals

• The safety, usability, technical performance, and efficacy are evaluated in the clinical trials and regulatory approvals of the neuromodulation solutions.
• Key players: Avania, Medpace, ICON plc.

Distribution to Hospitals, Pharmacies

• Specialized medical logistics networks and healthcare distributors are responsible for the distribution of neuromodulation systems to hospitals and pharmacies.
• Key players: Cardinal Health, CariMed, and McKesson.

Patient Support and Services

• 24/7 technical hotlines, dedicated patient ambassadors to assist individuals with devices, and remote programming apps are provided in the patient support and services of the neuromodulation systems.
• Key players: Medtronic plc, Boston Scientific Corporation, Abbott Laboratories.

Market Growth

The global neuromodulation market size was estimated at USD 9.84 billion in 2025 and is predicted to increase from USD 10.91 billion in 2026 to approximately USD 27.69 billion by 2035, expanding at a CAGR of 10.9% from 2026 to 2035.